| First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer BJ Solomon, T Mok, DW Kim, YL Wu, K Nakagawa, T Mekhail, E Felip, ... New England Journal of Medicine 371 (23), 2167-2177, 2014 | 3561 | 2014 |
| Panitumumab–FOLFOX4 treatment and RAS mutations in colorectal cancer JY Douillard, KS Oliner, S Siena, J Tabernero, R Burkes, M Barugel, ... New England Journal of Medicine 369 (11), 1023-1034, 2013 | 2576 | 2013 |
| Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer E Van Cutsem, M Peeters, S Siena, Y Humblet, A Hendlisz, B Neyns, ... Journal of clinical oncology 25 (13), 1658-1664, 2007 | 2409 | 2007 |
| Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with … JY Douillard, S Siena, J Cassidy, J Tabernero, R Burkes, M Barugel, ... Journal of clinical oncology 28 (31), 4697-4705, 2010 | 2206 | 2010 |
| Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial H Roché, P Fumoleau, M Spielmann, JL Canon, T Delozier, D Serin, ... Journal of Clinical Oncology 24 (36), 5664-5671, 2006 | 782 | 2006 |
| PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with … LS Schwartzberg, F Rivera, M Karthaus, G Fasola, JL Canon, JR Hecht, ... Journal of clinical oncology 32 (21), 2240-2247, 2014 | 770 | 2014 |
| Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study E Van Cutsem, F Rivera, S Berry, A Kretzschmar, M Michael, ... Annals of Oncology 20 (11), 1842-1847, 2009 | 701 | 2009 |
| Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer JY Douillard, S Siena, J Cassidy, J Tabernero, R Burkes, M Barugel, ... Annals of Oncology 25 (7), 1346-1355, 2014 | 635 | 2014 |
| Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGES‐3 M Marchand, P Weynants, E Rankin, F Arienti, F Belli, G Parmiani, ... International Journal of Cancer 63 (6), 883-885, 1995 | 593 | 1995 |
| Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study MC Garassino, BC Cho, JH Kim, J Mazières, J Vansteenkiste, H Lena, ... The Lancet Oncology 19 (4), 521-536, 2018 | 538 | 2018 |
| Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised … C Eng, TW Kim, J Bendell, G Argilés, NC Tebbutt, M Di Bartolomeo, ... The lancet oncology 20 (6), 849-861, 2019 | 436 | 2019 |
| Trastuzumab for patients with axillary-node–positive breast cancer: results of the FNCLCC-PACS 04 trial M Spielmann, H Roché, T Delozier, JL Canon, G Romieu, H Bourgeois, ... Journal of Clinical Oncology 27 (36), 6129-6134, 2009 | 369 | 2009 |
| Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic … S Giacchetti, G Bjarnason, C Garufi, D Genet, S Iacobelli, M Tampellini, ... Journal of clinical oncology 24 (22), 3562-3569, 2006 | 228 | 2006 |
| Cancer and renal insufficiency results of the BIRMA study N Janus, V Launay-Vacher, E Byloos, JP Machiels, L Duck, J Kerger, ... British journal of cancer 103 (12), 1815-1821, 2010 | 208 | 2010 |
| An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy E Van Cutsem, S Siena, Y Humblet, JL Canon, J Maurel, E Bajetta, ... Annals of Oncology 19 (1), 92-98, 2008 | 204 | 2008 |
| Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer JP Machiels, C Sempoux, P Scalliet, JC Coche, Y Humblet, E Van Cutsem, ... Annals of Oncology 18 (4), 738-744, 2007 | 192 | 2007 |
| Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with rectal cancer: the RadiOxCape study JP Machiels, L Duck, B Honhon, B Coster, JC Coche, P Scalliet, ... Annals of oncology 16 (12), 1898-1905, 2005 | 186 | 2005 |
| Neutrophil: lymphocyte ratio and intraoperative use of ketorolac or diclofenac are prognostic factors in different cohorts of patients undergoing breast, lung, and kidney … P Forget, JP Machiels, PG Coulie, M Berliere, AJ Poncelet, B Tombal, ... Annals of surgical oncology 20, 650-660, 2013 | 184 | 2013 |
| Safety and efficacy of buparlisib (BKM120) in patients with PI3K pathway-activated non-small cell lung cancer: results from the phase II BASALT-1 study JF Vansteenkiste, JL Canon, F De Braud, F Grossi, T De Pas, JE Gray, ... Journal of Thoracic Oncology 10 (9), 1319-1327, 2015 | 164 | 2015 |
| Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer CE Geyer Jr, JE Garber, RD Gelber, G Yothers, M Taboada, L Ross, ... Annals of oncology 33 (12), 1250-1268, 2022 | 160 | 2022 |
